전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved381 programs
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma · B-Cell Neoplasm

#B-CellNeoplasm#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 10Status Recruiting
CGTCurated CorestaleKitePhase 2

Tecartus (Tecartus)

Acute Lymphoblastic Leukemia; Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#BioJungboMoa-pick#cell-gene-therapy+4
Trials 9Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab+Pegaspargase (Sintilimab+Pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Phase2#monoclonal-antibody#NaturalKiller+3
Trials 8Status Recruiting
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 7Status Recruiting
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 7Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART19.1 (MB-CART19.1)

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory · Melanoma Stage III

#MelanomaStageIII#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 7Status Active
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 2

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 6Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 2

T cell injection targeting CD7 chimeric antigen receptor (T cell injection targeting CD7 chimeric antigen receptor)

CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Discontinued
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 2

ssCART-19 (ssCART-19)

B Cell Lymphoma · B Cell Lymphoma

#BCellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 5Status Recruiting
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
CGTLimited DatastaleStichting Hemato-Oncologie voor…Phase 2

ARI-0001 (ARI-0001)

NHL; DLBCL - Diffuse Large B Cell Lymphoma · NHL

#NHL#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTLimited DatastaleThe Affiliated Hospital of Xuzh…Phase 2

Anti-CD56 CAR T (Anti-CD56 CAR T)

Extranodal NK T Cell Lymphoma; NK-Cell Leukemia · Extranodal NK T Cell Lymphoma

#ExtranodalNKTCellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 4Status Recruiting

5 / 20 pages

← PreviousNext →